MedTrace Logo

A Study With Pentasa in Patients With Active Crohn's Disease

NCT00862121 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-03-16

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.

Conditions

  • Crohn´s Disease

Interventions

DRUG

Pentasa

6 g/day orally, 2 g in the morning and 4 g in the evening

DRUG

Placebo

6 g/day orally, 2 g in the morning and 4 g in the evening

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States
  • Belgium
  • Denmark
  • France
  • Germany
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00862121 on ClinicalTrials.gov